EUVIMEDEUVIMED entdecken
Crossref

Early and multiple doses of zoledronate mitigates rebound bone loss following withdrawal of receptor activator of nuclear factor kappa-B ligand inhibition

Kim AS, Taylor VE, Castro-Martinez A, Dhakal S, Zamerli A, Mohanty ST, Xiao Y, Simic MK, Pantalone A, Chu J, Cheng TL, Croucher PI und 3 weitere

Yearbook of Paediatric Endocrinology · 30.09.2025

DOI: 10.1530/ey.22.5.9 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Yearbook of Paediatric Endocrinology, online erschienen am 30.09.2025. Verfasst von Kim AS und 14 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Zitieren

APA

AS, K., VE, T., A, C., S, D., A, Z., ST, M., Y, X., MK, S., A, P., J, C., TL, C., PI, C., JR, C., CM, G., & MM, M. (2025). Early and multiple doses of zoledronate mitigates rebound bone loss following withdrawal of receptor activator of nuclear factor kappa-B ligand inhibition. Yearbook of Paediatric Endocrinology. https://doi.org/10.1530/ey.22.5.9

Vancouver

AS K, VE T, A C, S D, A Z, ST M, et al. Early and multiple doses of zoledronate mitigates rebound bone loss following withdrawal of receptor activator of nuclear factor kappa-B ligand inhibition. Yearbook of Paediatric Endocrinology. 2025. doi:10.1530/ey.22.5.9

BibTeX
@article{AS2025,
  author = {AS, Kim and VE, Taylor and A, Castro-Martinez and S, Dhakal and A, Zamerli and ST, Mohanty and Y, Xiao and MK, Simic and A, Pantalone and J, Chu and TL, Cheng and PI, Croucher and JR, Center and CM, Girgis and MM, McDonald},
  title = {Early and multiple doses of zoledronate mitigates rebound bone loss following withdrawal of receptor activator of nuclear factor kappa-B ligand inhibition},
  journal = {Yearbook of Paediatric Endocrinology},
  year = {2025},
  doi = {10.1530/ey.22.5.9}
}
Kostenlos starten →